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OBJECTIVES To clarify the healing process of disrupted culprit plaques of acute myocardial infarction (MI),
we serially observed the culprit plaques for 18 months after the onset of acute MI by
angioscopy.
BACKGROUND Although it has been reported that disruption of the yellow plaque and subsequent thrombosis
cause acute MI and that the thrombogenicity of the plaque lasts for a month, the healing
process of the plaque after disruption has not been clarified.
METHODS Eighty-five patients with acute MI were prospectively and consecutively enrolled. Angio-
scopic studies were performed immediately and at 1, 6 and 18 months after successful
reperfusion. The prevalence of yellow plaques and thrombus was examined. The color grade
of the plaque was determined as 0 (white), 1 (light yellow), 2 (yellow) or 3 (bright yellow).
RESULTS Although yellow plaque was present at the culprit lesion in most patients throughout
follow-up, its color grade was reduced from one to six months (1.9  0.6 vs. 1.1  0.7, p 
0.0003) after reperfusion, especially in the patients without hyperlipidemia (HL). The
incidence of thrombus was 92.5% immediately after reperfusion, which was reduced
significantly to 63.8%, 4.8% and 11.8% at 1, 6 and 18 months, respectively. The incidence of
thrombus (77.8% vs. 45.0%, p  0.03) at one month was higher in the patients with diabetes
mellitus (DM).
CONCLUSIONS The healing process of yellow plaques at the culprit lesions of MI was detected by angioscopy
as reductions of color grade and thrombogenicity at six months and partially at one month
after the onset of acute MI. This healing process appears to deteriorate by complicating cases
of DM or HL. (J Am Coll Cardiol 2001;38:1916–22) © 2001 by the American College of
Cardiology
Pathologic and angioscopic studies have revealed that dis-
ruption of lipid-rich yellow plaques and subsequent throm-
bosis play a major role in the development of acute myo-
cardial infarction (MI). It is important to determine how
long the thrombogenicity of the culprit plaques lasts, be-
cause re-thrombosis may cause re-infarction or post-
infarction angina and may worsen the prognosis of the
patients. We have previously reported, by angioscopic study
(1), that thrombus remains at the culprit lesions in 60% of
patients with MI, even at one month after the onset. Van
Belle et al. (2) have also suggested that angioscopic charac-
teristics of plaque instability last during one month after the
onset of MI. Smalling and Anderson (3) have commented
that plaque at culprit lesions frequently remains active for up
to 30 days after the onset of MI. However, the healing
process of those once-disrupted plaques has not been fully
clarified. The healing process is the process of reducing
thrombogenicity, which may be achieved by re-covering of
the disrupted plaques by neointima, with its functional
maturation. To elucidate the healing process of culprit
plaques, we angioscopically observed the culprit lesions of
MI at 1, 6 and 18 months after the onset.
METHODS
Patient selection. Patients with acute MI were prospec-
tively and consecutively enrolled from January 1995 to
December 1997. The entry criteria were: 1) acute MI
(confirmed by elevation of serum creatine kinase MB
fraction and angiographic demonstration of a culprit lesion)
with successful reperfusion; and 2) written, informed con-
sent for the examinations. The exclusion criteria were: 1)
left main coronary artery disease; and 2) coronary arteries
not suitable for angioscopic examination.
Study protocol. Angioscopic studies of the infarct-related
coronary arteries were performed immediately and at 1, 6
and 18 months after successful reperfusion. Reperfusion
therapy was performed with balloon angioplasty with or
without thrombolysis and stenting. Because only a few
patients underwent stenting, those patients were excluded.
Intravenous heparin (100 U/kg) was administered at the
beginning of catheterization, and the same amount was
added before angioplasty. Heparinization (8,000 to 10,000
U/day) was continued for a week. Oral aspirin (81 to 162
mg/day) was started as soon as possible in case there was no
contraindication. New antiplatelet agent glycoprotein IIb/
IIIa blockers were not used in any of the study patients,
because they have not been approved for clinical use in
Japan. Patients who received a repeat intervention of the
culprit lesion during follow-up were excluded from analysis
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thereafter. Data on the patients’ characteristics were col-
lected within a few weeks after hospital admission. Hyper-
lipidemic patients in this study were defined as: 1) patients
with serum total cholesterol 220 mg/dl (according to the
guidelines of the Japan Atherosclerosis Society); or 2)
patients already taking lipid-lowering drugs. Obesity was
defined as a body mass index of 26.4 kg/m2. The study
protocol was approved by the Ethical Committee of the
Osaka Police Hospital.
Angioscopic procedures and evaluations. Catheterization
was performed by the femoral approach, using an 8F sheath
and catheter. The coronary angiogram was recorded by the
Advantx medical system (General Electric). The angioscope
MC-800E (Nihon Kohden) and the optic fiber AS-003
(Nihon Kohden) were used. Angioscopic studies were made
while the blood was cleared away from view, by injection of
3% dextran-40, as previously reported (1). The angioscopic
images were recorded by a S-VHS videotape recorder. The
existence of yellow plaques and thrombus at the culprit
lesions and in the rest of the coronary segments was
evaluated. The color of the culprit plaques was graded as 0
(white), 1 (light yellow), 2 (yellow) or 3 (bright yellow),
according to the sample colors presented in Figure 1. The
number of yellow plaques (nYP) in a coronary artery,
excluding culprit lesions, was counted, and the maximal
color grade among those yellow plaques (maxYP) was
determined. The atherosclerosis index was calculated as
nYP maxYP. Angioscopic studies were performed by two
angioscopic specialists who had no knowledge of the back-
ground data of the patients, and in case of disagreement, a
third reviewer determined the evaluation.
Major adverse events and angioscopic findings. Data on
major adverse events (death, acute MI, unstable angina,
coronary artery bypass graft surgery [CABG] or percutane-
ous transluminal coronary angioplasty [PTCA]) that oc-
curred after the onset of acute MI, by the end of May 2001,
were collected from the clinical records. Angioscopically
determined variables of atherosclerosis (nYP, maxYP and
atherosclerosis index) immediately after reperfusion were
compared between patients who had an acute coronary
syndrome (ACS: acute MI or unstable angina) and those
who did not. The follow-up interval was 4.6  1.5 years.
Statistics. Continuous data are presented as the mean value
 SD. Changes in the prevalence of yellow plaques and
thrombus were analyzed by the Steel test, and changes in
the color grade of the plaques were analyzed by two-way,
repeated-measures analysis of variance (ANOVA). Differ-
ences in the patient characteristics between subgroups or the
effects of patient characteristics on thrombus or yellow
plaques were analyzed by ANOVA or the chi-square test. A
p value 0.05 was regarded as statistically significant.
RESULTS
Patient characteristics. Eighty-five patients were enrolled
in this study. As the reperfusion therapy, thrombolysis or
primary/rescue/delayed PTCA, or both, were performed.
Rescue PTCA was performed at 30 min after the admin-
istration of the thrombolytic agent (tissue plasminogen
activator). Delayed PTCA was performed at 1.8  1.7
months. Four patients who underwent stenting were ex-
cluded. Follow-up catheterization was not performed in 9,
16 and 34 patients at 1, 6 and 18 months, respectively,
because informed consent was not obtained. Due to a repeat
intervention of the culprit lesion before follow-up catheter-
ization, 9, 16 and 34 patients were excluded from analysis at
1, 6 and 18 months, respectively. Angioscopic studies were
not performed immediately and at 1, 6 and 18 months after
reperfusion in 26, 22, 36 and 14 patients, respectively,
because the angioscopic specialist was not available at the
time of examination. A clear angioscopic image was not
acquired in two patients, immediately after reperfusion and
at one month. Therefore, angioscopic observations were
successfully performed immediately and at 1, 6 and 18
months after reperfusion in 53, 47, 21 and 17 patients,
respectively. The characteristics of the study patients at each
time point are presented in Table 1. The angiographic
characteristics and method of reperfusion are presented in
Table 2. Patients with hyperlipidemia (HL) had signifi-
cantly higher serum total cholesterol levels (237  38 vs.
180  24 mg/dl, p  0.0001) and triglycerides (153  90
vs. 104  43 mg/dl, p  0.01) than those without HL. The
characteristics of the study patients with or without HL and
diabetes mellitus (DM) at each time point are presented in
Tables 3 and 4, respectively. There was no significant
difference in patient characteristics for any subgroup at any
time point (Tables 1–4).
Yellow plaques. Yellow plaques (Fig. 2A) remained at the
culprit lesions immediately and at 1, 6 and 18 months after
reperfusion in 94.3%, 100%, 85.7% and 82.4% of patients ,
respectively. A mild but significant reduction in the preva-
lence was detected at six months. The mean color grade of
Abbreviations and Acronyms
ACS  acute coronary syndrome
CABG  coronary artery bypass graft surgery
DM  diabetes mellitus
HL  hyperlipidemia
maxYP  maximal yellow plaque
MI  myocardial infarction
nYP  number of yellow plaques
PTCA  percutaneous transluminal coronary angioplasty
Figure 1. Color samples for the grading of yellow plaque.
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culprit yellow plaques (Fig. 2B) was reduced significantly
from one to six months (1.9  0.6 vs. 1.1  0.7, p 
0.0003) after reperfusion.
Although the color grade of the culprit plaques immedi-
ately after reperfusion and at one month was not signifi-
cantly influenced by any of the patient characteristics listed
in Table 1 or 2, the color grade at six months was
significantly higher in the patients with HL (1.4  0.6 vs.
0.7  0.5, p  0.03) (Fig. 3). In other words, the color
grade was reduced more in patients without HL (1.3 
0.8 vs.0.5 0.7, p 0.04). Other characteristics listed in
Table 1 or 2 had no significant influence on the reduction of
color grade. Although not statistically significant, the color
grade of the plaque at one month tended to be higher (2.1
0.7 vs. 1.8  0.6, p  0.08) (Fig. 4) in patients with DM,
in accordance with the higher prevalence of thrombus on
the plaque.
Thrombus on the culprit plaques. Thrombus (Fig. 2C)
was detected on the culprit plaques in 92.5% of patients
immediately after reperfusion, whereas it was decreased
significantly to 63.8% at 1 month and further to 4.8% and
11.8% at 6 and 18 months, respectively.
At one month, thrombus was detected more frequently in
patients with DM (77.8% vs. 45.0%, p  0.02) (Fig. 4).
Other characteristics listed in Table 1 or 2 had no influence
on the prevalence of thrombus. Plaques with thrombus had
a higher color grade (2.0  0.7 vs. 1.3  0.7, p  0.0001)
than those without thrombus, when analyzed by including
the data of all plaques at all time points.
Major adverse events and angioscopic findings. Ob-
served major adverse events were three deaths (1 suicide and
2 for unknown reasons), seven acute MIs (4 at original
culprit lesion and 3 at new lesion), two cases of unstable
angina (1 at original culprit lesion and 1 at new lesion) and
36 nonurgent coronary interventions (34 PTCA and 2
CABG). Angioscopic data had no significant association
with the incidence of all major adverse events. However,
angioscopically determined variables of atherosclerosis—
nYP (3.5  1.9 vs. 2.1  1.5, p  0.08), maxYP (2.5  0.6
vs. 1.7 0.9, p 0.09) and atherosclerosis index (9.5 6.8
vs. 4.4  4.0, p  0.02)—were larger in patients with ACS
than in those without it. The prevalence of thrombus at one
month was not associated with ACS events.
Table 1. Patients Characteristics
Total
(n  81)
Post-Reperfusion
Immediately
(n  53)
1 Month
(n  47)
6 Months
(n  21)
18 Months
(n  17)
Age (yrs) 62  9 62  9 61  9 62  8 66  7
Gender (male) 58 (72%) 40 (75%) 36 (77%) 14 (67%) 11 (65%)
Multi-vessel disease 35 (43%) 26 (49%) 19 (40%) 8 (38%) 8 (47%)
Coronary risk factors
Hypertension 33 (41%) 24 (45%) 22 (47%) 9 (43%) 5 (29%)
Diabetes mellitus 40 (49%) 24 (45%) 27 (57%) 13 (62%) 8 (47%)
Hyperlipidemia 54 (67%) 32 (60%) 27 (57%) 14 (67%) 14 (82%)
Smoking 9 (11%) 5 (9%) 5 (11%) 3 (14%) 2 (12%)
Obesity 11 (14%) 5 (9%) 7 (15%) 2 (10%) 1 (6%)
Serum lipid levels
Total cholesterol (mg/dl) 218  43 218  45 213  44 224  49 220  48
HDL cholesterol (mg/dl) 46  11 45  10 45  11 47  7 49  11
Triglycerides (mg/dl) 137  81 142  94 132  68 122  51 135  64
Medications
Beta-blockers 6 (7%) 6 (11%) 2 (4%) 3 (14%) 1 (6%)
ACE inhibitors 50 (62%) 34 (64%) 27 (57%) 11 (52%) 11 (65%)
Nitrate 73 (90%) 49 (92%) 42 (89%) 19 (90%) 13 (76%)
Calcium blockers 46 (57%) 31 (58%) 26 (55%) 17 (81%) 10 (59%)
Antiplatelet drugs 76 (94%) 50 (94%) 45 (96%) 21 (100%) 16 (94%)
Lipid-lowering drugs 39 (48%) 24 (45%) 16 (34%) 7 (33%) 11 (65%)
Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin-converting enzyme; HDL  high-density lipoprotein.
Table 2. Angiographic Characteristics and Method
of Reperfusion
Infarct-related vessel
LAD/LCx/RCA 48 (59%)/11 (14%)/22 (25%)
Diameter stenosis before intervention 99  3%
Diameter stenosis after intervention 33  18%
TIMI flow grade before intervention
0–1/2/3 59 (73%)/15 (19%)/7 (9%)
TIMI flow grade after intervention
2/3 2 (2%)/79 (98%)
Left ventricular ejection fraction* 52  15%
Method of reperfusion therapy
Primary PTCA 57 (70%)
Rescue PTCA 14 (17%)
Delayed PTCA 4 (5%)
Thrombolysis alone 6 (7%)
*Left ventricular ejection fraction was measured by left ventriculography at one-month
follow-up. Data are presented as the number (%) of patients or mean value  SD.
LAD  left anterior descending coronary artery; LCx  left circumflex coronary
artery; PTCA  percutaneous transluminal coronary angioplasty; RCA  right
coronary artery; TIMI  Thrombolysis In Myocardial Infarction trial.
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DISCUSSION
Stabilization of the culprit plaques in the healing process
after MI. The once-disrupted yellow plaques at the culprit
lesions of acute MI were accompanied by thrombus, sug-
gesting high thrombogenicity, in 64% of patients, even at
one month after the onset, as previously reported (1).
However, in the present study, those plaques were demon-
strated to lose thrombogenicity in the majority of patients at
six months after the onset of MI, when thrombus was
Table 3. Patient Characteristics for Figure 3
Post-Reperfusion
Immediately 1 Month 6 Months 18 Months
Without HL
(n  21)
With HL
(n  32)
Without HL
(n  20)
With HL
(n  27)
Without HL
(n  7)
With HL
(n  14)
Without HL
(n  3)
With HL
(n  14)
Age (yrs) 66 59 63 59 63 62 68 65
Gender (male) 16 (76%) 24 (75%) 16 (80%) 20 (74%) 5 (71%) 9 (64%) 2 (67%) 9 (64%)
Multi-vessel disease 10 (48%) 16 (50%) 9 (45%) 10 (37%) 1 (14%) 7 (50%) 2 (67%) 6 (43%)
Coronary risk factors
Hypertension 12 (57%) 12 (38%) 12 (60%) 10 (37%) 3 (43%) 6 (43%) 2 (67%) 3 (21%)
Diabetes mellitus 13 (62%) 11 (34%) 10 (50%) 17 (63%) 4 (57%) 9 (64%) 0 8 (57%)
Smoking 1 (5%) 4 (13%) 2 (10%) 3 (11%) 1 (14%) 2 (14%) 0 2 (14%)
Obesity 1 (5%) 4 (13%) 1 (5%) 6 (22%) 1 (14%) 1 (7%) 0 1 (7%)
Serum lipid levels
Total cholesterol (mg/dl) 175 246 178 237 184 244 177 229
HDL cholesterol (mg/dl) 42 47 42 47 44 49 50 49
Triglycerides (mg/dl) 103 167 109 148 108 129 94 144
Medications
Beta-blockers 2 (10%) 4 (13%) 1 (5%) 1 (4%) 1 (14%) 2 (14%) 0 1 (7%)
ACE inhibitors 14 (67%) 20 (63%) 12 (60%) 15 (56%) 3 (43%) 8 (57%) 2 (67%) 9 (64%)
Nitrate 17 (81%) 32 (100%) 18 (90%) 24 (89%) 6 (86%) 13 (93%) 2 (67%) 11 (79%)
Calcium blockers 13 (62%) 18 (56%) 9 (45%) 17 (63%) 4 (57%) 13 (93%) 1 (33%) 9 (64%)
Antiplatelet drugs 20 (95%) 30 (94%) 20 (100%) 25 (93%) 7 (100%) 14 (100%) 3 (100%) 13 (93%)
Lipid-lowering drugs 0 24 (75%) 0 16 (59%) 0 7 (50%) 0 11 (79%)
Data are presented as the mean value or number (%) of patients.
HL  hyperlipidemia; other abbreviations as in Table 1.
Table 4. Patient Characteristics for Figure 4
Post-Reperfusion
Immediately 1 Month 6 Months 18 Months
Without DM
(n  29)
With DM
(n  24)
Without DM
(n  20)
With DM
(n  27)
Without DM
(n  8)
With DM
(n  13)
Without DM
(n  9)
With DM
(n  8)
Age (yrs) 62 62 60 61 64 61 65 66
Gender (male) 23 (79%) 17 (71%) 17 (85%) 19 (70%) 7 (88%) 7 (54%) 7 (78%) 4 (50%)
Multi-vessel disease 16 (55%) 10 (42%) 9 (45%) 10 (37%) 4 (50%) 4 (31%) 4 (44%) 4 (50%)
Coronary risk factors
Hypertension 13 (45%) 11 (46%) 12 (60%) 10 (37%) 3 (38%) 6 (46%) 3 (33%) 2 (25%)
Hyperlipidemia 21 (72%) 11 (46%) 10 (50%) 17 (63%) 5 (63%) 9 (69%) 6 (67%) 8 (100%)
Smoking 3 (10%) 2 (8%) 2 (10%) 3 (11%) 1 (13%) 2 (15%) 1 (11%) 1 (13%)
Obesity 2 (7%) 3 (13%) 2 (10%) 5 (19%) 0 2 (15%) 0 1 (13%)
Serum lipid levels
Total cholesterol (mg/dl) 228 206 204 220 212 232 222 218
HDL cholesterol (mg/dl) 45 45 46 45 46 48 52 46
Triglycerides (mg/dl) 139 146 111 148 100 135 119 153
Medications
Beta-blockers 3 (10%) 3 (13%) 1 (5%) 1 (4%) 2 (25%) 1 (8%) 1 (11%) 0 (0%)
ACE inhibitors 20 (69%) 14 (58%) 12 (60%) 15 (56%) 4 (50%) 7 (54%) 6 (67%) 5 (63%)
Nitrate 27 (93%) 22 (92%) 18 (90%) 24 (89%) 7 (88%) 12 (92%) 7 (78%) 6 (75%)
Calcium blockers 16 (55%) 15 (63%) 10 (50%) 16 (59%) 7 (88%) 10 (77%) 5 (56%) 5 (63%)
Antiplatelet drugs 27 (93%) 23 (96%) 19 (95%) 26 (96%) 8 (100%) 13 (100%) 9 (100%) 7 (88%)
Lipid-lowering drugs 17 (59%) 7 (29%) 6 (30%) 10 (37%) 2 (25%) 5 (38%) 4 (44%) 7 (88%)
Data are presented as the mean value or number (%) of patients.
DM  diabetes mellitus; other abbreviations as in Table 1.
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detected in only 4.8% of the patients. In accordance with the
stabilization (reduction in thrombogenicity) of the plaques,
the color grade of the plaques was significantly reduced at
six months, when plaques even lost their yellow color
completely and became white in 14% of patients. The
disappearance of thrombus and yellow plaque at six months
after PTCA has been reported (4), with a small number of
patients with unstable angina. In the present study, we have
revealed the disappearance of thrombus and the regression
of yellow plaque in patients with acute MI by serial
examinations. Furthermore, we have revealed that the sta-
bilization of plaques are deteriorated in patients with DM or
HL. Because from one to six months after PTCA is the
period of active intimal proliferation after vascular injury, it
is likely that the neointima formed over the disrupted
plaques has stabilized the thrombogenic potential of the
plaques and reduced their color grade by separating the lipid
core from the blood flow.
Yellow color of the plaque and its instability. The rela-
tionship between the yellow color of the plaque and its
thrombogenicity or unstable clinical syndrome has been
established by angioscopic and pathologic studies (1,5,6),
and the yellow color of the plaque has been demonstrated to
be predictive of early adverse coronary events after PTCA
(7) in patients with ACS and of ACS (8) in patients with
stable effort angina. It has also been reported previously (8)
that the glistening yellow plaques cause ACS more fre-
Figure 2. Prevalence of yellow plaque at the culprit lesions (A), mean
(SD) color grade of the culprit plaque (B) and prevalence of thrombus at
the culprit plaques (C). Yellow plaques remained for as long as 18 months
at the culprit lesions of acute myocardial infarction, although the color
grade was reduced significantly and the prevalence was reduced mildly but
significantly from one to six months after reperfusion. The prevalence of
thrombus was decreased significantly from immediately to one month after
reperfusion, and further from one to six months. 0M  immediately after
reperfusion; M  month(s) after reperfusion. (A) *p  0.05 vs. 1 M. (B)
*p  0.005 vs. 1 M. (C) *p  0.005 vs. 0 M; †p  0.005 vs. 1 M.
Figure 3. Prevalence of thrombus (A) and mean (SD) color grade (B) in
patients with hyperlipidemia (HL) (solid bars) and patients without HL
(hatched bars). The prevalence of thrombus and the mean color grade
immediately after reperfusion and at one month were not different between
the patients with HL and those without HL. The mean color grade at six
months was significantly higher in the patients with HL. 0 M 
immediately after reperfusion; Mmonths after reperfusion. *p 0.05 vs.
patients without HL.
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quently than the nonglistening ones. The results of the
present study have suggested that yellow plaques of higher
color grades have a higher incidence of causing thrombus
formation. These results support the idea that the instability
of plaques are related with their yellow color, not only in the
process of plaque disruption, but also in the healing process
after disruption. The grading of yellow color may increase
the predictive value of the angioscopic examinations for
adverse coronary events.
Influence of DM and HL on the healing process. Al-
though the prevalence of yellow plaques and thrombus in
the culprit arteries of patients with unstable angina has been
reported (9) to be higher in those with DM, the present
study has revealed, for the first time, to the best of our
knowledge, that the prevalence of thrombus at the culprit
plaques of MI one month after the onset is higher in
patients with DM than in those without it, suggesting that
the thrombogenicity of the plaque is originally higher or the
healing process of the disrupted plaque is delayed in patients
with DM (Fig. 4). Because the color grade of the plaque at
one month tended to be higher in patients with DM,
although it was not different immediately after reperfusion,
the neointimal re-covering and thickening over the yellow
plaque may be delayed in those patients. In contrast, HL
delayed the reduction of color grade at six months, although
it had no significant effect on the prevalence of thrombus or
color grade immediately after reperfusion or at one month
(Fig. 3). The prevalence of thrombus at six months was too
low to reveal the difference between the patients with HL
and those without HL. The data on the non-HL subgroup
at 18 months might be biased because of the small sample
size (n  3).
Major adverse events and angioscopic findings.
Although the association between the presence of intracoro-
nary thrombus and an increased incidence of an adverse
outcome after PTCA and the association between the
presence of intracoronary thrombus and post-infarction
angina have been previously reported (10,11), we could not
detect the association between the presence of thrombus
and major adverse events in this study. One of the expla-
nations for this difference might be that the major adverse
events in this study happened rather remote from the onset
of the original MI and might have a different nature from
that of post-infarction angina or abrupt occlusion after
PTCA, as described in previous reports. However, we have
revealed that patients with ACS had more advanced yellow
plaque formation, and we believe that angioscopic exami-
nation of yellow plaque formation may be able to evaluate
the risk of future ACS.
Study limitations. This study has two major limitations: 1)
the study group was small, and thus the number of patients
followed up at 18 months became small; and 2) the
evaluation of plaque color was rather subjective, although
this kind of often-used grading system is easy and practical.
Although the prevalence of thrombus or plaque color at the
culprit lesions may possibly differ after different reperfusion
therapies (especially when a stent is implanted), study group
was too small to evaluate this effect. Although an unusually
high rate of patients had DM complications, no obvious
cause for this result was identified.
Conclusions. Disrupted yellow plaques at the culprit le-
sions of acute MI were accompanied by thrombus in 93% of
the patients immediately after reperfusion; however, the
incidence of thrombus detected at the plaque decreased to
64% at one month and to 5% at six months. According to
the reduction of thrombogenicity, the color grade of the
plaques was reduced. The higher color grade of the plaques
was associated with a higher incidence of thrombus. The
healing process of the culprit plaques of MI was angioscopi-
cally demonstrated as reductions in both the color grade and
incidence of thrombus of the plaques, which appeared to be
deteriorated in patients with HL or DM.
Reprint requests and correspondence: Dr. Yasunori Ueda, Car-
diovascular Division, Osaka Police Hospital, 10-31 Kitayama-cho,
Tennoji-ku, Osaka, 543-0035 Japan. E-mail: ueda@oph.gr.jp.
Figure 4. Prevalence of thrombus (A) and mean (SD) color grade (B) in
patients with diabetes mellitus (DM) (solid bars) and patients without
DM (hatched bars). The prevalence of thrombus and the mean color grade
immediately after reperfusion were not different between the patients with
HL and without DM. The prevalence of thrombus was significantly higher
and the mean color grade tended (p  0.08) to be higher in the patients
with DM at one month. The mean color grade at six months was not
different between the patients with DM and those without DM. 0 M 
immediately after reperfusion; Mmonths after reperfusion. *p 0.05 vs.
patients without DM.
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